Significantly lower TLF rates (2.8% versus 7.8%, p=0.020) with DynamX® compared to Resolute Onyx DES with no new events in bioadaptor arm between 3 and 4 years 88% reduction in Cardiovascular Death (0 ...

China's centralized procurement program for coronary stents has lower costs for patients without compromising clinical ...

Purpose: The mechanism of action and pharmacokinetics of sirolimus when used as part of a drug-eluting stent (DES) and the efficacy and cost of using DESs versus bare-metal stents are discussed.

DUBLIN--(BUSINESS WIRE)--The "Global Coronary Stents Market - Focused Insights 2024-2029" report has been added to ResearchAndMarkets.com's offering. The Global Coronary Stents Market was valued at ...

The recent approval by the US Food and Drug Administration (FDA) of the Absorb GT1 bioresorbable vascular scaffold (BVS) system (Abbott Vascular) got me thinking about a modern-day medical problem: ...

While the placement of stents in newly reopened coronary arteries has been shown to reduce the need for repeat angioplasty procedures, researchers from the Duke Clinical Research Institute have found ...

A new report published Tuesday found over one in five coronary stents placed between 2019 and 2021 were unnecessary, costing Medicare $800 million a year and putting patients at risk of complications ...

Drug-eluting coronary-artery stents have been shown to decrease restenosis and therefore the likelihood that additional procedures will be required after percutaneous coronary intervention (PCI). We ...

Drug-eluting stents (DES) have revolutionized the practice of interventional cardiology over the past decade. Although their efficacy has never been called into question, concerns have been raised ...